Wen Liang Wang

Title: Innovations of Wen Liang Wang

Introduction

Wen Liang Wang is a notable inventor based in Anhui, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel compounds for medical applications. With a total of two patents to his name, his work focuses on addressing critical health issues through innovative solutions.

Latest Patents

Wang's latest patents include "Pyrazole derivatives and use thereof" and "EZH2 inhibitor and use thereof." The first patent provides a novel PDGFR kinase inhibitor, which comprises a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite, or prodrug thereof. This invention outlines the use and method of the compound for preventing or treating conditions associated with PDGFR kinase activity, particularly those related to PDGFRα and/or PDGFRβ kinase activity. The second patent presents an inhibitor of both wild type and Y641F mutant of human histone methyltransferase EZH2. This compound can be utilized to treat cancers or precancerous conditions linked to EZH2 activity.

Career Highlights

Wen Liang Wang is currently associated with Therapeutics Science Inc., where he continues to advance his research and development efforts. His work has garnered attention for its potential impact on cancer treatment and other medical conditions.

Collaborations

Wang collaborates with several talented individuals in his field, including Jing Liu and Ao Li Wang. These partnerships enhance the innovative capacity of his research and contribute to the success of their projects.

Conclusion

Wen Liang Wang's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to advancing medical science. His work not only addresses significant health challenges but also showcases the importance of collaboration in research and development.